Lintuzumab-CD28/CD3ζ CD33 CAR-T immunotherapy is now under evaluation in a preclinical trial involving children and adolescents/young adults with relapsed/refractory acute myeloid leukemia (AML) [43]. This evidence concerns the gene CD247 and acute myeloid leukemia.